Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Ptc Therapeutics (PTCT) over the last 5 years, with Q1 2025 value amounting to $2000.0.

  • Ptc Therapeutics' Deferred Taxes rose 30000.0% to $2000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was -$55.9 million, marking a year-over-year decrease of 1914.04%. This contributed to the annual value of -$55.9 million for FY2024, which is 1913.91% down from last year.
  • As of Q1 2025, Ptc Therapeutics' Deferred Taxes stood at $2000.0, which was up 30000.0% from -$55.9 million recorded in Q4 2024.
  • Ptc Therapeutics' 5-year Deferred Taxes high stood at $4.0 million for Q4 2023, and its period low was -$55.9 million during Q4 2024.
  • For the 3-year period, Ptc Therapeutics' Deferred Taxes averaged around -$11.4 million, with its median value being -$2000.0 (2023).
  • As far as peak fluctuations go, Ptc Therapeutics' Deferred Taxes crashed by 150512.69% in 2024, and later soared by 30000.0% in 2025.
  • Ptc Therapeutics' Deferred Taxes (Quarter) stood at $4.0 million in 2023, then plummeted by 1505.13% to -$55.9 million in 2024, then soared by 100.0% to $2000.0 in 2025.
  • Its last three reported values are $2000.0 in Q1 2025, -$55.9 million for Q4 2024, and -$3000.0 during Q3 2024.